论文部分内容阅读
The title compound，[Cu2(C7H5O2)4(C2H6O)2]，was synthesized by the reaction of benzoic acid，copper acetate and ethanol in an aqueous solution.Trypan blue dye exclusion method was used in experiment.X-ray single-crystal analysis has revealed that compound 1 (C32H32Cu2O10)crystallizes in the monoclinic system，space group C2／c，Mr=703.66，a=47.340(5)，b=6.6613(4)，C=22.028(2)(A)，β=113.284(4)°，V=6380.6(10)(A)3，Z=8，Dc=1.465 g／cm3，F(000)=2896，μ=1.388 mm-1，the final R=0.0515 and wR=O.1172 for 5712 observed reflections with I>2σ(I).X-ray crystal structure analysis suggests that compound [Cu2[C7H5Oz]4(C2H6O)2]has a binuclear structure with two Cu(п)atoms coordinated by four benzoate groups and two ethanol molecules.The crystal packing is stabilized by intermolecular O-H-O hydrogen bonds.The compound inhibits the proliferation of K562 cells(chronic myeloid leukemic cells)significantly and dose-dependently in 48 h,and IC50 of K562 is 17.μg／mL by trypan blue dye exclusion method.